Background Various trials have compared the efficacy and toxicity of liposomal doxorubicin-
based chemotherapy with the conventional formulation of doxorubicin although arriving at …

There is accumulating evidence that molecular phenotyping of breast cancer determines the
timing, pattern, and outcome of metastatic disease. The most clinically relevant subtypes are …

The treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast
cancer has been revolutionized by trastuzumab. However, longer survival of these patients …

Certain chemotherapeutic agents and mediastinal irradiation can be cardiotoxic and place
cancer survivors at risk for developing advanced heart failure (HF). Anthracyclines are the …

Background: The aim of the present study was to evaluate clinicopathological characteristics
of our early stage breast cancer patients who are epidermal growth factor receptor 2 (HER2) …

Brain metastases (BMs) represent a major issue in clinical practice and are associated with
a significant worsening of patient's quality of life and, often, a dismal prognosis. Breast …

Background The combination of trastuzumab and chemotherapy is currently considered the
standard of care for patients with locally advanced/operable human epidermal growth factor …

Background/Aim: Trastuzumab therapy, the standard treatment for human epidermal growth
factor receptor type-2 (HER2)-positive breast cancer, is associated with possible …

An increasing number of advanced breast cancer patients develop overt brain metastases.
This is partly due to recent advances in therapies for visceral metastases that extend life of …

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more
aggressive subtype of breast cancer and targeting the HER2 receptor has proven effective in …